NCT06797362

Brief Summary

The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.

Trial Health

73
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
10 countries

35 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 22, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 28, 2025

Completed
Last Updated

February 17, 2026

Status Verified

January 1, 2026

First QC Date

January 22, 2025

Last Update Submit

February 12, 2026

Conditions

Interventions

Oral tablet

Also known as: Zidesamtinib

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥18 years.
  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement.
  • Previously received at least 1 prior ROS1 TKI, with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician.
  • Enrollment in a clinical trial of zidesamtinib is not possible.
  • Adequate organ function and bone marrow reserve.

You may not qualify if:

  • Prior receipt of zidesamtinib.
  • Previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol.
  • Ongoing anti-cancer therapy.
  • Eligible for ongoing clinical trial with zidesamtinib

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (35)

University of Colorado Anschutz School of Medicine

Aurora, Colorado, 80045, United States

AVAILABLE

University of Chicago Medical Center

Chicago, Illinois, 60637, United States

AVAILABLE

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

AVAILABLE

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

AVAILABLE

Memorial Sloan Kettering Cancer Center

Manhattan, New York, 10065, United States

AVAILABLE

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

AVAILABLE

University of Washington / Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States

AVAILABLE

Chris O'Brien Lifehouse

Camperdown, New South Wales, 2050, Australia

AVAILABLE

Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia

AVAILABLE

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

AVAILABLE

Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

AVAILABLE

Centre Leon Berard

Lyon, Auvergne-Rhône-Alpes, 69008, France

AVAILABLE

GCS IUCT Oncopole

Toulouse, Occitanie, 31059, France

AVAILABLE

CHU de Nantes

Nantes, Pays de la Loire Region, 44800, France

AVAILABLE

Institut Gustave Roussy

Villejuif, Île-de-France Region, 94800, France

AVAILABLE

IRCCS Istituto Tumori Giovanni Paolo II

Bari, 70124, Italy

AVAILABLE

L'Istituto Europeo di Oncologia S.r.l.

Milan, 20141, Italy

AVAILABLE

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, 20133, Italy

AVAILABLE

IRCCS Istituto Oncologico Veneto

Padua, 35128, Italy

AVAILABLE

AUSL della Romagna - Ravenna

Ravenna, 48121, Italy

AVAILABLE

Istituto Nazionale Tumori "Regina Elena

Roma, 00144, Italy

AVAILABLE

Antoni van Leeuwenhoek Hospital

Amsterdam, 1006 BE, Netherlands

AVAILABLE

Netherlands Cancer Institute: NKI

Amsterdam, 1066 CX, Netherlands

AVAILABLE

University Medical Center Groningen

Groningen, 9713 GZ, Netherlands

AVAILABLE

National University Hospital Singapore

Singapore, 119074, Singapore

AVAILABLE

National Cancer Centre Singapore

Singapore, 168583, Singapore

AVAILABLE

Uomi Cancer Center-Clinica Tres Torres

Barcelona, 08017, Spain

AVAILABLE

Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain

AVAILABLE

Gregorio Marañón General University Hospital

Madrid, 28007, Spain

AVAILABLE

Hospital Univ Doce de Octubre

Madrid, 28041, Spain

AVAILABLE

National Cheng Kung University Hospital

Tainan, 70403, Taiwan

AVAILABLE

National Taiwan University Hospital

Taipei, 100229, Taiwan

AVAILABLE

The Royal Marsden Hospital

Sutton, Surrey, SM2 5PT, United Kingdom

AVAILABLE

The Royal Marsden Hospital

London, SM2 5PT, United Kingdom

AVAILABLE

The Christie Hospital

Manchester, M20 4BX, United Kingdom

AVAILABLE

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Contact for Program Information

CONTACT

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2025

First Posted

January 28, 2025

Last Updated

February 17, 2026

Record last verified: 2026-01

Locations